Pharma Focus Asia

MaSTherCell SA Announces New Manufacturing Facility in Belgium


MaSTherCell SA announced new manufacturing facility in Belgium for cell and gene therapy products.


The company has signed a lease agreement for a 5,700m2 (61,354ft²) facility located in Belgium.

The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially approved cell and gene therapy products.

This new site will significantly expand MaSTherCell’s current European manufacturing capacity.

MaSTherCell will continue to use its existing site for both industrialisation and early to mid-stage clinical programs.

In addition, the facility will be included with industry 4.0 precepts such as software integration, intelligent equipment and integrated processes with the objective to provide cell and gene therapy community.

The manufacturing facility is expected to be operational in early 2021.

This state-of-the-art plant will create several hundred jobs and Belgian expertise needs to train the teams.


NameMaSTherCell SA
TypeNew Construction
Parties InvolvedMaSTherCell SA
ScheduleScheduled to be operational in 2021
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference